Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-27T03:33:53.906Z Has data issue: false hasContentIssue false
  • English
  • Français

Factors Associated with the Use of Fecal Microbiota Transplant in Patients with Recurrent Clostridium difficile Infections

Published online by Cambridge University Press:  24 January 2018

Sehrish Jamot ,
Vikram Raghunathan ,
Kavin Patel ,
Colleen R. Kelly  and
Seah H. Lim
Sehrish Jamot
Affiliation:
Department of Medicine, Rhode Island Hospital/Brown University Warren Alpert Medical School, Providence, Rhode Island
Vikram Raghunathan
Affiliation:
Department of Medicine, Rhode Island Hospital/Brown University Warren Alpert Medical School, Providence, Rhode Island
Kavin Patel
Affiliation:
Department of Medicine, Rhode Island Hospital/Brown University Warren Alpert Medical School, Providence, Rhode Island
Colleen R. Kelly
Affiliation:
Department of Medicine, Rhode Island Hospital/Brown University Warren Alpert Medical School, Providence, Rhode Island
Seah H. Lim*
Affiliation:
Division of Hematology and Oncology, Department of Medicine, Rhode Island Hospital/Brown University Warren Alpert Medical School, Providence, Rhode Island
*
Address correspondence to Seah H. Lim, MD, PhD, Division of Hematology and Oncology, Room 149, APC Building, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903 ([email protected]).
Get access Rights & Permissions [Opens in a new window]

Abstract

OBJECTIVE

To identify the factors associated with first Clostridium difficile infection (CDI) that predict fecal microbiota transplantation (FMT) for recurrent CDI

DESIGN

We carried out a retrospective single-center cohort study to compare the clinical characteristics of 200 patients who underwent FMT for recurrent CDI to 75 patients who did not.

SETTING

A single academic hospital in the United States

PATIENTS

Adult patients

RESULTS

The time from first to second CDI correlated to subsequent FMT use. Concomitant inflammatory bowel disease (IBD; P=.002), use of immunosuppressive therapy (P=.04), and use of metronidazole within 2 months before the first CDI (P=.02) correlated positively to subsequent FMT in univariate analysis. The use of oral vancomycin for first CDI was more common in those who required FMT than those who did not in univariate (P=.02) and multivariate (P=.03) analyses. In contrast, intravenous vancomycin use within 2 months before the first CDI reduced the risk for FMT in univariate P=.000003) and multivariate (P=.0001) analyses. Black patients with recurrent CDI were less likely to receive FMT than white patients (P=.00005). Patients who received FMT were also less likely to have comorbidities.

CONCLUSIONS

This study provides important insights into the factors predictive for FMT in patients with recurrent CDI and highlights the potential racial and medical characteristics that affect the access of the patients to FMT.

Infect Control Hosp Epidemiol 2018;39:302–306

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 39 , Issue 3 , March 2018 , pp. 302 - 306
Copyright
© 2018 by The Society for Healthcare Epidemiology of America. All rights reserved 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

a

Authors of equal contribution

References

REFERENCES

1. DePestel, DD, Aronoff, DM. Epidemiology of Clostridium difficile infection. J Pharm Pract 2014;26:464–475.Google Scholar
2. Miller, BA, Chen, LF, Sexton, DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011;32:387–390.CrossRefGoogle ScholarPubMed
3. Eiseman, B, Silen, W, Bascom, GS, et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44:854–859.Google ScholarPubMed
4. van Nood, E, Vrieze, A, Nieuwdorp, M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile . N Engl J Med 2013;368:407–415.CrossRefGoogle ScholarPubMed
5. Currie, BP, Lemos-Filho, L. Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycin-resistant enterococci. Antimicrob Agent Chemother 2004;48:4427–4429.CrossRefGoogle ScholarPubMed
6. Heisel, RW, Sutton, RR, Mascara, GP, et al. Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine. Leuk Lymphoma 2017;Mar 28:1–8; doi: 10.1080/10428194.2017.1306645.Google Scholar
7. Stevens, VW, Nelson, RE, Schwab-Daugherty, EM, et al. Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection. JAMA Intern Med 2017;177:546–553.CrossRefGoogle ScholarPubMed
8. Kim, HB, Wang, Y, Sun, X. A detrimental role of immunosuppressive drug, dexamethasone, during Clostridium difficile infection in association with a gastrointestinal microbial shift. J Microbiol Biotechnol 2016;26:567–571.CrossRefGoogle ScholarPubMed
9. Tourret, J, Willing, BP, Dion, S, et al. Immunosuppressive treatment alters secretion of ileal antimicrobial peptides and gut microbiota, and favors subsequent colonization by uropathogenic Escherichia coli . Transplantation 2017;101:74–82.Google Scholar
10. Maloy, KJ, Powrie, F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474:298–306.CrossRefGoogle ScholarPubMed
11 Argamany, JR, Delgado, A, Reveles, KR. Clostridium difficile infection health disparities by race among hospitalized adults in the United States, 2001 to 2010. BMC Infect Dis 2016;16:454.CrossRefGoogle ScholarPubMed
12. Freedberg, DE, Salmasian, H, Friedman, C, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013;108:1794–1801.CrossRefGoogle ScholarPubMed
13. Yang, S, Rider, BB, Baehr, A, et al. Racial and ethnic disparities in health care-associated Clostridium difficile infections in the United States: state of the science. Am J Infect Control 2016;44:91–96.CrossRefGoogle ScholarPubMed
14. Carethers, JM. Should African Americans be screened for colorectal cancer at an earlier age? Nat Clin Pract Gastroenterol Hepatol 2005;2:352–353.CrossRefGoogle ScholarPubMed